News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,564 Results
Type
Article (136)
Company Profile (1)
Press Release (1427)
Section
Business (438)
Career Advice (1)
Deals (54)
Drug Development (433)
FDA (25)
Job Trends (20)
News (865)
Policy (59)
Tag
2024 Bio NC Digital (1)
Academia (21)
Alliances (85)
ALS (1)
Alzheimer's disease (23)
Approvals (24)
Artificial intelligence (1)
Best Places to Work (11)
Biotechnology (1)
Bladder cancer (1)
Cancer (2)
Career advice (1)
Cell therapy (1)
Clinical research (322)
Collaboration (2)
Compensation (2)
COVID-19 (8)
Data (8)
Diagnostics (7)
Drug discovery (1)
Earnings (164)
Events (200)
Executive appointments (2)
FDA (28)
Funding (6)
Gene therapy (10)
Government (5)
Healthcare (53)
Immunology and inflammation (1)
Infectious disease (8)
Intellectual property (1)
IPO (23)
Job creations (10)
Job search strategy (1)
Layoffs (4)
Legal (3)
Medical device (14)
Medtech (14)
Mergers & acquisitions (31)
Multiple sclerosis (3)
Neurodegenerative disease (5)
Neuroscience (33)
NextGen: Class of 2025 (16)
Non-profit (16)
Northern California (6)
Parkinson's disease (1)
Patents (1)
People (166)
Phase I (126)
Phase II (178)
Phase III (86)
Pipeline (5)
Policy (1)
Postmarket research (8)
Preclinical (42)
Rare diseases (10)
Real estate (4)
Regulatory (56)
Research institute (9)
Rett syndrome (3)
Series B (1)
Southern California (4)
Spinal muscular atrophy (1)
Startups (13)
The Weekly (1)
United States (72)
Date
Last 7 days (4)
Last 30 days (10)
Last 365 days (121)
2025 (37)
2024 (151)
2023 (108)
2022 (140)
2021 (171)
2020 (113)
2019 (97)
2018 (57)
2017 (53)
2016 (49)
2015 (68)
2014 (64)
2013 (49)
2012 (62)
2011 (71)
2010 (66)
Location
Arizona (1)
Asia (55)
Australia (9)
California (14)
Canada (7)
Connecticut (3)
Europe (211)
Florida (3)
Illinois (4)
Kentucky (1)
Massachusetts (24)
New Jersey (2)
New York (16)
North Carolina (1)
Northern California (6)
Ohio (1)
Pennsylvania (1)
Rhode Island (1)
South America (1)
Southern California (4)
Texas (2)
Washington State (2)
1,564 Results for "neurogene".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
·
2 min read
·
Annalee Armstrong
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Neurogene to Participate in Upcoming Conferences
February 24, 2025
·
1 min read
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Neurogene Announces Addition to Russell 3000® Index
Neurogene Inc. today announced that Neurogene will be added to the Russell 3000 ® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024.
July 1, 2024
·
5 min read
Pharm Country
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. today announced that Company management will participate in the following conferences.
June 5, 2024
·
2 min read
Press Releases
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
April 28, 2025
·
5 min read
Press Releases
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
March 24, 2025
·
10 min read
Press Releases
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
April 3, 2025
·
8 min read
Pharm Country
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. today announced that Company management will participate in the following investor conferences.
February 29, 2024
·
1 min read
1 of 157
Next
